Clinical Trial Update: A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CJC-1134-PC injection in antidiabetic treatment-naive patients with inadequately controlled Type 2 diabetes completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CJC-1134-PC Injection

Snippet

Sponsor: Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | Conditions: Type 2 Diabetes Mellitus - Poor Control | Phase 3 | Status: COMPLETED